Celsion

Celsion is an integrated biopharmaceutical company that focuses on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. Its lead product candidate ThermoDox®, is a proprietary heat-activated liposomal encapsulation of doxorubicin that is currently in a phase 3 trial combined with RFA for treating hepatocellular carcinoma, it also has GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian cancer.

Celsion has 3 platform technologies that provide the basis for the development of a range of therapeutics for the treatment of cancers. With these technologies, Celsion is working to develop and commercialize more efficient and targeted oncology therapies, maximizing efficacy while minimizing side effects common to cancer treatments.

Celsion has the mission to revolutionalize the landscape of cancer treatment with novel targeting technologies. Its goal is to cure cancers.